Clinical Trial Update: Evaluation of Canakinumab in High-Risk Former-Smokers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluation of canakinumab in high-risk former smokers with lung cancer; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Peter Shields | Conditions: Cigarette Smoking-Related Carcinoma, Lung Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING